Obulytix

Obulytix is focused on the development of the next generation enzyme-based antibiotics to address the rapidly expanding antimicrobial resistance crisis. Our inspiration comes from nature by exploiting the power of phage lysins, highly performant enzymes produced by bacteriophages to rapidly kill bacteria. This novel class of antibiotics fulfills all innovation criteria for antibiotics as defined by the World Health Organization (WHO). Our company runs the most advanced development platform for phage lysins, empowered by artificial intelligence (AI), to address the high medical need of new antibiotics targeting multidrug-resistant bacteria. Reach out to us if you wish to collaborate.